5-chloro-2-{1-[3-([1,4]diazepane-1-carbonyl)-4-fluoro-phenyl]-ethoxy}-benzamide | 960244-61-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-chloro-2-{1-[3-([1,4]diazepane-1-carbonyl)-4-fluoro-phenyl]-ethoxy}-benzamide
• 英文别名: 5-Chloro-2-[1-[3-(1,4-diazepane-1-carbonyl)-4-fluorophenyl]ethoxy]benzamide
• CAS: 960244-61-5
• 化学式: C₂₁H₂₃ClFN₃O₃
• 分子量: 419.883
• InChiKey: ZTYQQWVICQBVIW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  29
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  84.7
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• COMPOSITIONS AND METHODS FOR TREATING AND/OR PREVENTING CANCER BY INHIBITING FATTY ACID BINDING PROTEINS
  申请人：Lengyel Ernst

  公开号：US20120289570A1

  公开（公告）日：2012-11-15

  The present invention concerns methods and compositions for the inhibition or reduction of the primary tumor and metastasis by inhibition of fatty acid binding proteins.
• Compositions and Methods for Treating and/or Preventing Cancer by Inhibiting Fatty Acid Binding Proteins
  申请人：The University of Chicago

  公开号：US20140363522A1

  公开（公告）日：2014-12-11

  The present invention concerns methods and compositions for the inhibition or reduction of the primary tumor and metastasis by inhibition of fatty acid binding proteins.
• US8748470B2
  申请人：——

  公开号：US8748470B2

  公开（公告）日：2014-06-10
• [EN] DIAGNOSTIC TEST FOR PREDICTING RESPONSIVENESS TO TREATMENT WITH POLY(ADP-RIBOSE) POLYMERASE (PARP) INHIBITOR<br/>[FR] TEST DE DIAGNOSTIC POUR PRÉDIRE LA SENSIBILITÉ À UN TRAITEMENT PAR UN INHIBITEUR DE POLY(ADP-RIBOSE) POLYMÉRASE
  申请人：ASTRAZENECA AB

  公开号：WO2011058367A2

  公开（公告）日：2011-05-19

  The present invention relates generally to methods for treating cancer and to methods of predicting the responsiveness of a cancer cell to therapeutic treatment. In particular, the invention provides the identities of genes (biomarkers) that may be used to identify populations or individuals of cancer sufferers that are likely to respond favourably to treatment with a Poly (ADP - Ribose) polymerase (PARP) inhibitor. In a preferred embodiment, the expression levels of at least one base excision repair biomarker from Table 1 (including at least PARP-1), at least one homologous recombination biomarker from Table 2 and at least one proliferation biomarker from Table 3 are measured.